A number of other analysts have also recently weighed in on ONXX. Analysts at Bernstein initiated coverage on shares of Onyx Pharmaceuticals in a research note to investors on Thursday, May 24th. They set an “outperform” rating and a $74.00 price target on the stock. Separately, analysts at Robert W. Baird reiterated a “neutral” rating on shares of Onyx Pharmaceuticals in a research note to investors on Tuesday, May 22nd. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Onyx Pharmaceuticals in a research note to investors on Friday, May 4th. They now have a $45.00 price target on the stock.
Onyx Pharmaceuticals opened at 41.70 on Monday. Onyx Pharmaceuticals has a 1-year low of $27.17 and a 1-year high of $47.80. The company has a market cap of $2.684 billion and a price-to-earnings ratio of 38.65.
Onyx Pharmaceuticals last released its earnings data on Wednesday, May 2nd. The company reported ($0.68) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.60) by $0.08. The company’s quarterly revenue was up 7.3% on a year-over-year basis. Analysts expect that Onyx Pharmaceuticals will post $-0.61 EPS next quarter.
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer.